Hidden messages in fluids: A review of clinical and fundamental perspectives on post‐lymph node dissection drains

• Published in: International journal of cancer Vol. 156; no. 6; pp. 1103 - 1113
• Main Authors: Mak, Chon‐Hou, Wang, Guang‐Rui, Li, Zi‐Zhan, Cao, Lei‐Ming, Zhang, Chen‐Xi, Zhu, Zhao‐Qi, Liu, Bing, Bu, Lin‐Lin
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 15.03.2025; Wiley Subscription Services, Inc
• Subjects: Biomarkers, Tumor; Biopsy; Body fluids; Body Fluids - chemistry; cytokine; Dissection; Drainage - methods; extracellular vesicles; Exudates and Transudates - chemistry; Humans; Immune response; Inflammation; liquid biopsy; Liquid Biopsy - methods; lymph node dissection; Lymph Node Excision - adverse effects; Lymph nodes; Lymphatic drainage; Lymphatic system; Medical wastes; Patients; postoperative drainage fluid; Prognosis; Therapeutic targets; Wound drainage; cytokine; lymph node dissection; extracellular vesicles; postoperative drainage fluid; liquid biopsy
• ISSN: 0020-7136; 1097-0215; 1097-0215
• DOI: 10.1002/ijc.35240

In recent years, there has been a growing interest in liquid biopsy due to its non‐invasive diagnostic value. Postoperative drainage fluid (PDF) is the fluid exudate from the wound site following lymph node dissection. PDF is regarded as a medical waste with no specific clinical significance. Nevertheless, the liquid biopsy of PDF may enable the reuse of this fluid. PDF contains a variety of body fluids, including blood and lymph. PDF contains a variety of biological components, including cytokines, extracellular vesicles (EVs), proteins, nucleic acids, cells and bacteria. These components are indicative of the postoperative inflammatory response, the immune response and the therapeutic response. In this review, we examine the current state of research in the field of liquid biopsy in PDF, elucidating how the analysis of its components can assess the prognosis of patients after lymph node dissection, monitor real‐time changes in patient status, and identify new biomarkers and potential therapeutic targets.